Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
about
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.Hitting the Bull's-Eye in Metastatic Cancers-NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death.Cancer Chemotherapy Specific to Acidic Nests.Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow.Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism.Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.
P2860
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Inhibition of IL-6 expression ...... of atorvastatin and celecoxib.
@en
Inhibition of IL-6 expression ...... of atorvastatin and celecoxib.
@nl
type
label
Inhibition of IL-6 expression ...... of atorvastatin and celecoxib.
@en
Inhibition of IL-6 expression ...... of atorvastatin and celecoxib.
@nl
prefLabel
Inhibition of IL-6 expression ...... of atorvastatin and celecoxib.
@en
Inhibition of IL-6 expression ...... of atorvastatin and celecoxib.
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of IL-6 expression ...... of atorvastatin and celecoxib.
@en
P2093
Allan H Conney
Huaqian Wang
Jeremiah Van Doren
Mou-Tuan Huang
Robert S Dipaola
Susan Goodin
Xiao-Xing Cui
Xiaodong Cheng
P2860
P304
P356
10.3892/OR.2013.2885
P577
2013-11-29T00:00:00Z